Oncolys
is a Public company. Oncolys generates $395.6K in revenue per employee Oncolys has 2 companies in its portfolio, and its first investment was made in 2015. Oncolys has 1 followers on Owler.Oncolys
is a Public company. Oncolys generates $395.6K in revenue per employee Oncolys has 2 companies in its portfolio, and its first investment was made in 2015. Oncolys has 1 followers on Owler.
CEO
- -News
Feb 09, 2024
Marketscreener
Oncolys: Oncolys BioPharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Oct 28, 2023
Pharamceutical Technology
Oncolys: Suratadenoturev by Oncolys BioPharma for Gastric Cancer: Likelihood of Approval
Oct 16, 2023
MarketScreener
Oncolys: Oncolys BioPharma : Achievement of Primary Endpoint for Efficacy in the Phase2 Clinical Trial for Telomelysin-Radiation Combination Therapy
Aug 04, 2023
Marketscreener
Oncolys: Oncolys BioPharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
Jun 06, 2023
MarketScreener
Oncolys: ASCO 2023 ANNOUNCEMENT: Encouraging Preliminary Data of OBP-301 with Pembrolizumab in refractory gastroesophageal adenocarcinoma
May 12, 2023
MarketScreener
Oncolys: Oncolys BioPharma : Non-consolidated Financial Results for the Three Months Ended March 31, 2023
Nov 04, 2022
MarketScreener
Oncolys: Oncolys BioPharma : Non-consolidated Financial Results for the Nine Months Ended September 30, 2022
Aug 23, 2022
Owler
Oncolys BioPharma Inc: Oncolys's revenue changed from $6.60M in Mar 2022 to $7.12M in Jun 2022
Aug 17, 2022
MarketScreener
Oncolys: Oncolys BioPharma : Announcement of Completion of Enrollment in Phase IIa Clinical Trial of OBP-601 (censavudine, TPN-101) in Patients with Progressive Supranuclear Pals
Dec 07, 2021
MarketScreener
Oncolys: Oncolys BioPharma : First Patient Dosed in NRG Oncology Phase I Clinical Trial for Telomelysin(OBP-301)-Chemoradiation Combination Therapy for Esophageal Cancer Patients